ADIL - ADIAL PHARMACEUTICALS, INC.

1.63
0.010   0.613%

Share volume: 77,767
Last Updated: 04-17-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.19%

PREVIOUS CLOSE
CHG
CHG%
$1.62
0.01
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 24%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.16%
1 Month
-12.83%
3 Months
653.58%
6 Months
348.67%
1 Year
150.77%
2 Year
-15.54%
Key data
Stock price
$1.63
P/E Ratio 
N/A
DAY RANGE
$1.60 - $1.66
EPS 
-$3.59
52 WEEK RANGE
$0.13 - $3.67
52 WEEK CHANGE
$150.77
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
1.428 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-12-2025
BETA 
0.84
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$77,102
AVERAGE 30 VOLUME 
$89,607
Company detail
CEO: Cary J. Claiborne
Region: US
Website: adialpharma.com
Employees: 20
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction.

Recent news